Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 56Neoplasms 14NSCLC 11Brain Neoplasms 11Neoplasm Metastasis 10Carcinoma 9Meningeal Carcinomatosis 6Colorectal Neoplasms 5Bronchial Neoplasms 5Thoracic Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Prostatic Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer With EGFR T790M Mutation × osimertinib × Clear all
NCT03257124 2021-08-16

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Samsung Medical Center

Phase 2 Unknown
80 enrolled
Thoracic

Non-Small Cell Lung Cancer With EGFR T790M Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡